Want to join the conversation?
Pharmaceutical and chemical company $MRK posted 3Q15 GAAP earnings of $0.64 per share vs. $0.31 per share in 3Q14. During the quarter, the company advanced the clinical development program for KEYTRUDA, a drug approved by the FDA for the treatment of advanced melanoma and metastatic NSCLC.
I haven’t seen a drop in banks like this in a long time. Looks like $WFC is still facing pressures from its sales practices scandal..!!
Helping President-elect's America first focus, $WMT set to create 10,000 retail jobs in the US in 2017.
Looks like Trump has his eyes on the $MON and Bayer merger next. He had a meeting with the CEOs and apparently got job promises from them.